GenAI’s potential to revolutionize drug safety monitoring with adverse event validation
The healthcare industry currently generates about 30 percent of the world’s data volume and that number is expanding rapidly, reaching an annual growth rate of 36 percent by next year. The life sciences are a major contributor to the expansion of the healthcare industry’s data, with a market growth rate of 11 percent up until 2032. In particular, drug development and monitoring continue to expand as the volume of information and variety of sources used in data collection increase. Organizations are now challenged with not only gathering and collecting data but also validating potential safety events.